title: A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.
abstract: OBJECTIVE
  To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma.
  
  
  METHODS
  Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily × 32 fractions=57.6 Gy) plus weekly cisplatin (40 mg/m(2)) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor.
  
  
  RESULTS
  A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N=4), toxicity (N=9), death (N=2), other (N=3). There were 37 patients with a complete clinical response (37/58; 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes.
  
  
  CONCLUSIONS
  This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.
authors.affiliation: Gynecologic Oncology of Indiana, Indianapolis, IN 46237, USA. David.Moore@ssfhs.org
authors.forename: David H
authors.initials: DH
authors.lastname: Moore
authors.forename: Shamshad
authors.initials: S
authors.lastname: Ali
authors.forename: Wui-Jin
authors.initials: WJ
authors.lastname: Koh
authors.forename: Helen
authors.initials: H
authors.lastname: Michael
authors.forename: Mack N
authors.initials: MN
authors.lastname: Barnes
authors.forename: Carolyn K
authors.initials: CK
authors.lastname: McCourt
authors.forename: Howard D
authors.initials: HD
authors.lastname: Homesley
authors.forename: Joan L
authors.initials: JL
authors.lastname: Walker
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D014846:Vulvar Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin